Self-reported reactogenicity of COVID-19 vaccines with and without influenza coadministration duri

Article metadata and authorship

The PubMed entry lists a multi-author study titled "Self-reported reactogenicity after COVID-19 vaccination with and without influenza vaccine coadministration during pregnancy in Canada" published in Vaccine (2026 Oct 24:92:129122). The DOI is 10.1016/j.vaccine.2026.129122. Sophie Tran is the lead named author and the paper carries contributions from a large, multi‑institution Canadian author group and the COVERED Team. The record classifies the item as a free article accessible through the journal and indicates the bibliographic details necessary to locate the full text.

What the PubMed record provides and what it omits

The PubMed page provides complete bibliographic metadata (title, author list, affiliations, DOI, journal citation) and confirms open access to the article. The record does not, however, include the study abstract or the primary data in the source text supplied here. As a result, the present summary cannot reproduce numerical outcomes, reactogenicity rates, comparative statistics, or any trial-specific endpoints because those elements were not present in the retrieved PubMed content.

The article listing does show the publication date and indexing details. It does not report critical methodological items in the extracted content: sample size, study design (randomized trial, observational cohort, surveillance), inclusion/exclusion criteria, follow-up intervals, or definitions of reactogenicity used by the investigators. The PubMed text accessible here also lacks vaccine-specific information (manufacturer, platform, dose number) and the timing or protocol of coadministration with the influenza vaccine.

Public affiliations and collaborative network reported

Authors are affiliated with multiple Canadian institutions, including university obstetrics and gynecology departments, pediatrics divisions, public-health schools, and provincial health programs. The listing includes affiliations at the University of British Columbia, McMaster University, University of Toronto, Université de Montréal, University of Calgary, University of Manitoba, Dalhousie University and others, together with the COVERED Team collaborators. This distribution indicates a broad, national collaborative effort across obstetrics, pediatrics and vaccine-evaluation centers in Canada.

The presence of the COVERED Team as a corporate collaborator implies coordinated surveillance or multicenter data collection, but the PubMed record excerpt does not define the network’s operational role, data sources, or governance. Readers should consult the full article for clarity on how sites contributed and how data were pooled or harmonized.

Missing methodological and outcome details in the available record

The supplied PubMed content does not include primary study methods or results. The following key items are absent from the retrieved text and therefore cannot be asserted here:

• Sample size and participant demographics (age ranges, trimester at vaccination, comorbidities)
• Study design (prospective/retrospective cohort, randomized, passive surveillance)
• Vaccine products assessed (COVID-19 vaccine brand or platform; influenza vaccine formulation)
• Timing of coadministration relative to pregnancy gestation and to COVID-19 dose number
• Definitions and grading of reactogenicity events (local vs systemic; severity criteria)
• Quantitative reactogenicity outcomes or comparative statistics between coadministration and non-coadministration groups
• Adverse pregnancy, fetal, or neonatal outcomes, if assessed

Because these items were not reported in the accessible PubMed snippet, investigators’ reported reactogenicity rates, any statistical comparisons, and safety inferences cannot be relayed here. The record’s bibliographic completeness permits retrieval of the full text, but the abstract and results were not present in the source content provided for this rewrite.

Clinical questions unresolved by the PubMed entry

The PubMed listing raises concrete clinical questions that remain unanswered within the provided record. Those questions include:

• How many pregnant people contributed reactogenicity data and what were their demographic characteristics?
• Which COVID-19 vaccine products were included, and were specific formulations linked to different reactogenicity profiles?
• Was influenza vaccine coadministration given on the same day and in the same limb; was timing standardized?
• What were the observed rates of local versus systemic reactogenicity, and were differences statistically evaluated?
• Did investigators assess any pregnancy-specific safety endpoints or neonatal outcomes in relation to coadministration?

The PubMed record confirms authorship and easy access to the full article, but it does not provide the data needed to answer these items. Clinicians and guideline authors should consult the journal's full text via the DOI or the Vaccine website to review the investigators’ methods, numeric results and the authors’ stated limitations before drawing clinical inferences.

Limitations of this summary

This editorial rewrite relies exclusively on the PubMed metadata and author/affiliation information present in the supplied source text. No abstract, methods, results, tables, or figures were included in the source content that I was given. Consequently, I have not reported effect sizes, safety signals, or any findings that were not explicitly present in the PubMed record excerpt. For definitive clinical interpretation — including reactogenicity frequency estimates, subgroup analyses, and any recommendations on coadministration in pregnancy — consult the article’s full text using DOI 10.1016/j.vaccine.2026.129122 or the Vaccine journal link cited on PubMed.